Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $178.45 USD
Change Today -14.54 / -7.53%
Volume 731.4K
PBYI On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:15 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

puma biotechnology inc (PBYI) Snapshot

Open
$187.86
Previous Close
$192.99
Day High
$189.81
Day Low
$170.31
52 Week High
08/26/14 - $279.37
52 Week Low
06/4/14 - $53.63
Market Cap
5.7B
Average Volume 10 Days
298.6K
EPS TTM
$-4.72
Shares Outstanding
32.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PUMA BIOTECHNOLOGY INC (PBYI)

puma biotechnology inc (PBYI) Related Businessweek News

No Related Businessweek News Found

puma biotechnology inc (PBYI) Details

Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

120 Employees
Last Reported Date: 03/2/15
Founded in 2010

puma biotechnology inc (PBYI) Top Compensated Officers

Founder, Chairman of The Board, Chief Executi...
Total Annual Compensation: $910.0K
Senior Vice President of Finance & Administra...
Total Annual Compensation: $421.9K
Senior Vice President of Clinical Research an...
Total Annual Compensation: $475.8K
Compensation as of Fiscal Year 2014.

puma biotechnology inc (PBYI) Key Developments

Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients

Puma Biotechnology, Inc. has expanded the second cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). The cohort that has been expanded is the cohort that includes patients with metastatic non-small cell lung cancer and whose tumors have a HER2 mutation. The Phase II basket trial, which was initiated in October 2013, is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating (driver) ERBB mutations, including epidermal growth factor receptor (EGFR), HER2 and HER3. The cohorts (baskets) included in the study are (1) bladder/urinary tract cancer; (2) breast cancer; (3) colorectal cancer; (4) endometrial cancer; (5) gastric/esophageal cancer; (6) ovarian cancer; (7) all other solid tumors with a HER2 mutation; (8) EGFR mutated and/or amplified primary brain cancer; and (9) solid tumors with a HER3 mutation. The non-small cell lung cancer (NSCLC) patients initially entered the study in the “other solid tumors with a HER2 mutation” basket and due to the preliminary activity seen in the trial the company has expanded the basket, as per the protocol for the trial. The expanded HER2 mutant NSCLC basket will now enroll a total of 18 patients.

Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer

Puma Biotechnology, Inc. announced the initiation of a Phase II trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer. The 70 patient study will be an open label single arm Phase II trial of PB272 monotherapy administered to patients with HER2-positive early stage breast cancer who have previously received adjuvant treatment with trastuzumab. Patients will receive extended adjuvant treatment with neratinib for a period of one year. Patients will receive primary prophylaxis with high dose loperamide (16 mg per day initially) in order to attempt to reduce the neratinib-related diarrhea. The primary endpoint of the trial is reduction in the incidence and severity of diarrhea.

Puma Biotechnology, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Puma Biotechnology, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $47.6 million against $16.0 million a year ago. Net loss was $47.5 million or $1.57 per share compared to $15.9 million or $0.56 per share for the same period last year. Non-GAAP adjusted net loss was $31.1 million or $1.03 per share against $12.8 million or $0.45 per share a year ago. Net cash used in operating activities for the fourth quarter of 2014 was $18.5 million. For the year, the company reported loss from operations of $142.3 million against $54.8 million a year ago. Net loss was $142.0 million or $4.73 per share compared to $54.6 million or $1.90 per share for the same period last year. Net cash used in operating activities was $77.2 million compared with $55.0 million for the same period last year. Non-GAAP adjusted net loss was $102.8 million or $3.43 per share against $47.1 million or $1.64 per share a year ago. Net cash used in operating activities for the full year 2014 was $77.2 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBYI:US $178.45 USD -14.54

PBYI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBYI.
View Industry Companies
 

Industry Analysis

PBYI

Industry Average

Valuation PBYI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 49.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PUMA BIOTECHNOLOGY INC, please visit www.pumabiotechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.